Download PDF
kleintier konkret 2014; 17(2): 21-29
DOI: 10.1055/s-0033-1361538
hund
neurologie
Enke Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG Stuttgart

Therapie der Epilepsie beim Hund

Thomas Flegel
Dipl. ACVIM (Neurology), Dipl. ECVN, European Specialist in Veterinary Neurology, Klinik für Kleintiere, Universität Leipzig
› Author Affiliations
Further Information

Publication History

Publication Date:
28 April 2014 (online)

Also available at
    Permissions and Reprints All articles of this category

Die idiopathische Epilepsie zählt zu den häufigsten chronischen neurologischen Erkrankungen des Hundes, deren Inzidenz mit bis zu 5,7 % angegeben wird [[1]]. Die meisten der betroffenen Tiere benötigen eine medikamentelle Therapie, die einmal initiiert, dann meistens lebenslang weitergeführt werden muss.

 

  • Literatur

  • 1 Chandler K. Canine epilepsy: what can we learn from human seizure disorders?. Vet J 2006; 172: 207-217
    CrossrefGoogle Scholar
  • 2 Dewey CW. Anticonvulsant therapy in dogs and cats. Vet Clin North Am Small Anim Prac 2006; 36: 1107-1127
    Google Scholar
  • 3 Dewey CW, Cerda-Gonzales S, Levine JM et al. Pregabalin as an adjunct to phenobarbital, potassium bromide, or a combination of phenobarbital and potassium bromide for treatment of dogs with suspected idiopathic epilepsy. J Am Vet Med Assoc 2009; 235: 1442-1449
    CrossrefGoogle Scholar
  • 4 Fischer A, Hülsmeyer V. Ätiologie und Pathogenese. In: Die idiopathische Epilepsie des Hundes. Stuttgart: Enke; 2013: 11-27
    Google Scholar
  • 5 Kiviranta AM, Laitinen-Vapaavuori O, Hielm-Björkman A et al. Topiramte as add-on antiepileptic drug in treating refractory canine idiopathic epilepsy. J Small Anim Pract 2013; 54: 512-520
    Google Scholar
  • 6 von Kloppmann T, Rambeck B, Tipold A. Prospective study of zonisamide therapy for refractory idiopathic epilepsy in dogs. J Small Anim Pract 2007; 48: 134-138
    CrossrefGoogle Scholar
  • 7 Löscher W, Hönack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998; 284: 474-479
    Google Scholar
  • 8 Monteiro R, Anderson TJ, Innocent G et al. Variations in serum concentration of phenobarbitone in dogs receiving regular twice daily doses in relation to the times of administration. Vet Rec 2009; 165: 556-558
    CrossrefGoogle Scholar
  • 9 Penderis J, Volk H. Switching between medications for the management of epilepsy in dogs. Vet Rec 2013; 173: 323-324
    CrossrefGoogle Scholar
  • 10 Podell M. Seizures. In: Platt SR, Olby NJ. eds. BSAVA Manual of Canine and Feline Neurology. Quedgeley: British Small Animal Veterinary Association; 2004: 97-112
    Google Scholar
  • 11 Rieck S, Rundfeldt C, Tipold A. Anticonvulsant activity and tolerance of ELB138 in dogs with epilepsy: a clinical pilot study. Vet J 2006; 172: 86-95
    CrossrefGoogle Scholar
  • 12 Rossmeisl JH, Inzana KD. Clinical signs, risk factors, and outcomes associated with bromide toxicosis (bromism) in dogs with idiopathic epilepsy. J Am Vet Med Assoc 2009; 234: 1425-1431
    CrossrefGoogle Scholar
  • 13 Schwartz-Porsche D, Jürgens U. Effectiveness of bromide in therapy resistant epilepsy in dogs. Tierarztl Prax 1991; 19: 395-401
    Google Scholar
  • 14 Schwartz-Porsche D, Löscher W, Frey HH. Therapeutic efficacy of phenobarbital and primidone in canine epilepsy: a comparison. J Vet Pharmacol Ther 1985; 8: 113-119
    CrossrefGoogle Scholar
  • 15 Volk H, Loderstedt S. Neuigkeiten in der Behandlung von Epilepsie bei Hund und Katze. Kleintierpraxis (Sonderdruck) 2011; 56: 649-664
    Google Scholar